Welcome to our dedicated page for Unity Btech SEC filings (Ticker: UBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Unity Biotechnology, Inc.'s SEC filings document a biotechnology issuer's corporate status, capital structure and governance after clinical-stage work in senolytic therapeutics. Recent 8-K and Form 25 filings cover Nasdaq listing-compliance notices, suspension and removal of the common stock from Nasdaq listing, OTC quotation under UNBX, and related corporate-status disclosures.
Proxy and current-report filings also describe stockholder voting matters, material definitive agreements, the issuance and rights of a Series A Preferred Stock share, board and officer changes, and amendments to governing documents. Other disclosures address common-stock registration, liquidity, operating reductions and formal communications around strategic alternatives for UNITY's ophthalmology assets.
Unity Biotechnology, Inc. (UBX) is asking stockholders to approve a Plan of Complete Liquidation and Dissolution at a virtual Special Meeting on September 18, 2025 to authorize the Board to wind down the company. Only holders of record as of July 25, 2025 may vote; as of that date there were 17,212,172 shares of Common Stock outstanding and one share of Series A Preferred Stock that carries 600,000,000 votes and will vote in proportion to Common Stock votes on the Dissolution Proposal. The Board unanimously recommends a vote "FOR" the Dissolution and Adjournment proposals.
The Board approved the Dissolution and Plan of Dissolution on June 27, 2025, concurrently accepting the resignations of the CEO, CFO and CLO and reducing the Board from eight directors to one, appointing Craig R. Jalbert to lead the wind-down. The company ceased clinical development and expects to use remaining cash to pay winding-up costs first; based on information available at the time of this proxy statement, the Board expects there will not be any amounts available for distribution to stockholders. The company also disclosed its Common Stock was suspended from Nasdaq on July 9, 2025 and has been trading on the OTC Markets.
Unity Biotechnology, Inc. (UBX) filed a Form 25 indicating that the Nasdaq Stock Market LLC will remove UBX common stock from listing and registration under Section 12(b) of the Exchange Act. Nasdaq’s 2025-08-06 submission certifies compliance with Rule 12d2-2 requirements for delisting; the filing references both Exchange-initiated 12d2-2(b) and Issuer-initiated 12d2-2(c) pathways but does not specify which box is checked. No financial metrics, earnings data, or major transactions accompany the notice. Once effective (generally after 10 calendar days), UBX shares will no longer trade on Nasdaq, shifting to over-the-counter markets unless another listing venue is secured.